Scientific Industries, Inc. reported its financial results for the third quarter and the first nine months of fiscal year 2025, revealing a mixed performance amid significant operational changes. For the three months ended September 30, 2025, the company generated revenues of $1.404 million, a 5.2% increase from $1.334 million in the same period last year. However, for the nine months ended September 30, 2025, total revenues decreased by 2.5% to $3.427 million compared to $3.515 million in the prior year. The company recorded a net income of $3.994 million for the quarter, a substantial turnaround from a net loss of $1.180 million in the same quarter of 2024, primarily due to a gain of $5.263 million from the sale of its Genie product line.
The financial performance reflects a strategic shift following the divestiture of the Genie Division, which was completed on August 7, 2025. This sale, which included a purchase price of $9.6 million, has allowed the company to streamline its operations and focus on its core business segments, namely Benchtop Laboratory Equipment and Bioprocessing Systems. The company’s total assets increased to $14.557 million as of September 30, 2025, up from $11.561 million at the end of 2024, driven by a significant rise in cash and investment securities.
Operationally, the company reported a decrease in gross profit margins, with the gross profit percentage for the three months ending September 30, 2025, at 45.5%, down from 51.0% in the prior year. This decline was attributed to the absence of Genie Division sales and increased material costs. General and administrative expenses rose slightly to $803,600, while selling expenses decreased to $735,900, reflecting a reduction in sales and marketing personnel. Research and development expenses also saw a minor decline, indicating a cautious approach to investment in new product development.
Looking ahead, Scientific Industries anticipates continued challenges in the Bioprocessing Systems segment due to market softness and customer delays. The company expects to leverage the cash generated from the Genie Division sale to support its operations and strategic initiatives over the next year. Despite the ongoing negative cash flows from operations, management believes that the current cash position, bolstered by the recent asset sale, will be sufficient to fund operations for at least the next twelve months. The company remains focused on enhancing its product offerings and improving operational efficiencies as it navigates the evolving market landscape.
About SCIENTIFIC INDUSTRIES INC
Scientific Industries, Inc. designs, manufactures, and markets benchtop laboratory equipment and bioprocessing systems for research institutions, pharmaceutical companies, and laboratories. Its core products include mixers, shakers, incubators, and measurement devices, with a focus on innovative bioprocessing solutions incorporating smart sensors and software. Serving global markets, the company leverages direct sales and distributor networks, emphasizing product development and intellectual property to maintain competitive advantages.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.